# $nbi

Biotech stocks are seeing mixed performance, with some commercial-stage companies showing reasonable multiples while others face speculation and extended PDUFA dates. The XBI and IBB indices reflect broader market sentiment in the sector.

### About $nbi
This topic covers news and analysis of publicly traded biotechnology companies, particularly those in the clinical and commercial stages of drug development.  

### Top $nbi Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"YTD % change in SP comm'l-stage non-oncology focused bios w/MC of 1-$5.5B $OCUL $SNY rumor has fizzled out $TARS JPM excl Insider sales Last PR dated [--] mos ago $TVTX multiples appear reasonable. FSGS PDUFA ext Best $ARDX $NVAX $MIRM $LQDA $OGN even $CORT $XBI $IBB $NBI"  
[X Link](https://x.com/NightOwlBiotech/status/2017650553623281710) [@NightOwlBiotech](/creator/x/NightOwlBiotech) 2026-01-31T17:25Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing